Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1/2 1

Status

Completed 1Active not recruiting 1

Sponsor Class

OTHER 11NETWORK 3NIH 2INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Head & Neck 2

Conditions

Breast Neoplasms 35Prostatic Neoplasms 26Carcinoma, Non-Small-Cell Lung 24Lung Neoplasms 15Squamous Cell Carcinoma of Head and Neck 8Ovarian Neoplasms 8Carcinoma, Ovarian Epithelial 7Adenocarcinoma of Lung 7Inflammatory Breast Neoplasms 6Fallopian Tube Neoplasms 6Breast Neoplasms, Male 6Stomach Neoplasms 4Head and Neck Neoplasms 4Unspecified Adult Solid Tumor, Protocol Specific 3Tongue Neoplasms 3Pain 3Neoplasm Metastasis 3Adenocarcinoma, Bronchiolo-Alveolar 3Uterine Cervical Neoplasms 2Urinary Bladder Neoplasms 2Sarcoma 2Salivary Gland Neoplasms 2Pleural Effusion, Malignant 2Oropharyngeal Neoplasms 2Neoplasms 2Lymphoid Interstitial Pneumonia 2Endometrial Neoplasms 2Carcinoma, Transitional Cell 2Carcinoma 2Brenner Tumor 2

Interventions

Cetuximab 7Magnetic Resonance Spectroscopy 5Radiotherapy 4Erlotinib Hydrochloride 4Cisplatin 4Bevacizumab 4Trastuzumab 3Specimen Handling 3Radiotherapy, Conformal 3Carboplatin 3sargramostim 2ixabepilone 2Vorinostat 2Sorafenib 2SS1(dsFv)PE38 2Radiotherapy, Intensity-Modulated 2Radiosurgery 2Paclitaxel 2N-(3-chloro-4-((3-fluorobenzyl)oxy)phenyl-6-(5-((methylsulfonyl)ethyl)aminomethyl)-2-furyl)-4-quinazolinamine 2Lapatinib 2Fluorouracil 2Fluorodeoxyglucose F18 2Docetaxel 2Dasatinib 2Chemotherapy, Adjuvant 2Biopsy 2trastuzumab deruxtecan 1tipifarnib 1temsirolimus 1temoporfin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
NIH × Salivary Gland Neoplasms × Docetaxel × Clear all
NCT00588770 2026-05-29

Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

National Cancer Institute (NCI)

Phase 3 Active not recruiting
403 enrolled 10 charts
Head & Neck

Lymphoid Interstitial Pneumonia, Squamous Cell Carcinoma of Head and Neck, Salivary Gland Neoplasms, Tongue Neoplasms

NCT00055770 2013-11-25

Erlotinib Plus Docetaxel in Treating Patients With Locally Advanced, Metastatic, or Recurrent Head and Neck Cancer

National Cancer Institute (NCI)

Phase 1/2 Completed
45 enrolled
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Salivary Gland Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡